PreludeDx™ Announces Publication of Residual Risk Data After Radiation Therapy in the International Journal of Radiation Oncology•Biology•Physics

DCISionRT® is the first and only test to identify DCIS Patients at Surprisingly High Residual Risk After Surgery and Radiotherapy

LAGUNA HILLS, CA., September 20, 2022 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, today announced the release of clinical study data in the International Journal of Radiation Oncology· Biology· Physics (“Red Diary”). The study demonstrated that the DCISionRT® residual risk subtype (RRt) identified patients with ductal carcinoma in situ (DCIS) who were at significantly higher risk of recurrence after breast-conserving surgery (BCS) and radiation therapy (RT). The risk profile of these patients may warrant intensified or alternative treatment considerations.

This study, titled “New biosignature identifies patients with DCIS at high risk of local recurrence after breast-conserving surgery and radiation therapy,” evaluated the risk of recurrence at 10 years in 926 women diagnosed with DCIS and treated with BCS with or without RT. Patients in the RRt group had a 42% risk of recurrence after BCS and a significantly elevated recurrence rate of 14.7% after BCS and RT.

“DCISionRT can help identify women who may benefit from intensified or alternative treatment, as they are at surprisingly high risk of recurrence after standard treatment for DCIS,” said Frank Vicini, MD, radiation oncologist at GenesisCare, member of NRG Oncology and co-first author of the study. “This study demonstrates new utility and evidence in providing DCIS patients and their physicians with unique and valuable information beyond clinical and pathological features to determine treatment decisions based on a patient’s personal tumor biology. woman.”

“Knowing whether a patient will receive minimal or significant benefit from radiation therapy, or whether she may need more intensive treatment, helps me and my colleagues provide truly personalized treatment to our patients with DCIS. “, said Julie A. MargenthalerMD, FACS, Professor of Surgery, University of Washington School of Medicine, and co-author of the study. “DCISionRT is an extremely valuable test for planning surgical and adjuvant (post-surgical) treatments.”

“We are grateful for the multinational collaboration that has resulted in results published in ASTRO’s official scientific journal,” said Dan Forche, President and CEO of PreludeDx. “The Residual Risk Subtype is an important advancement for patients and physicians, reinforcing our commitment to help guide the optimal management of patients with DCIS with our proprietary DecisionTree^MT risk profile and treatment outcomes.”

About DCISionRT for Breast DCIS

DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts the benefit of radiation therapy. Patients with DCIS have cancer cells lining the milk ducts of the breast, but they have not spread to surrounding breast tissue. In the United States, more than 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from University of California San Francisco, and building on research that began with funding from the National Cancer Institute, helps doctors better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman’s individual tumor biology as well as other disease risk factors and provide personalized recurrence risk. The test provides a decision score^MT which identifies a woman’s risk as low or high. Unlike other risk assessment tools, the DCISionRT assay combines protein expression from seven biomarkers and four clinicopathologic factors, using a nonlinear algorithm to account for multiple interactions between individual factors to better interpret complex biological information. DCISionRT’s smart reports provide a woman’s risk of recurrence after breast-conserving surgery alone and with the addition of radiation therapy. In turn, this new information can help patients and their doctors make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx is focused on developing precision breast cancer tools that will impact a patient’s treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden on the healthcare system. Before making a treatment decision, Know Your Risk™. PreludeDx is a portfolio company of Fjord Ventures.

For more information on how PreludeDx is making a difference for patients, please visit the company’s website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, DecisionTree, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in United States and foreign countries.

SOURCE PreludeDx